Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABA(A) potentiating activity for use in dementia

BACKGROUND: Synaptic dysfunction is a key event in pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD) where synapse loss pathologically correlates with cognitive decline and dementia. Although evidence suggests that aberrant protein production and aggregation are the causati...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Neurosci
Päätekijät: Luo, Jia, Lee, Sue H., VandeVrede, Lawren, Qin, Zhihui, Piyankarage, Sujeewa, Tavassoli, Ehsan, Asghodom, Rezene T., Aissa, Manel Ben, Fà, Mauro, Arancio, Ottavio, Yue, Lan, Pepperberg, David R., Thatcher, Gregory R. J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2015
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4612403/
https://ncbi.nlm.nih.gov/pubmed/26480871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12868-015-0208-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia